Myriad Genetics, Inc., a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The company offers molecular diagnostic tests, including myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; riskScore, a clinically validated personalized medicine tool; GeneSight, a DNA genotyping test to optimize psychotropic drug selection for neuroscience patients; and Tumor BRACAnalysis CDx, a DNA sequencing test that is designed to be utilized to predict response to DNA damaging agents. It also provides Vectra DA, a protein quantification test for assessing the disease activity of rheumatoid arthritis; Prolaris, a RNA expression test for assessing the aggressiveness of prostate cancer; EndoPredict, a RNA expression test for assessing the aggressiveness of breast cancer; myPath Melanoma, a RNA expression test for diagnosing melanoma; and myChoice HRD, a companion diagnostic to measure three modes of homologous recombination deficiency. In addition, Myriad Genetics, Inc. offers biomarker discovery, and pharmaceutical and clinical services to the pharmaceutical, biotechnology, and medical research industries; and operates an internal medicine emergency hospital primarily for internal medicine and hemodialysis. The company has collaboration with AstraZeneca for the development of an indication for BRACAnalysis CDx. Myriad Genetics, Inc. was founded in 1991 and is headquartered in Salt Lake City, Utah.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Diagnostic substances
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:MYGN
CUSIP62855J10
Phone801-584-3600
Debt
Debt-to-Equity Ratio0.01
Current Ratio3.19
Quick Ratio2.86
Price-To-Earnings
Trailing P/E Ratio36.88
Forward P/E RatioN/A
P/E Growth2.72
Sales & Book Value
Annual Sales$772.60 million
Price / Sales4.28
Cash Flow$1.9839 per share
Price / Cash22.31
Book Value$13.62 per share
Price / Book3.25
Profitability
EPS (Most Recent Fiscal Year)$1.20
Net Income$131.10 million
Net Margins17.69%
Return on Equity9.78%
Return on Assets7.46%
Miscellaneous
Employees2,400
Outstanding Shares74,720,000
Market Cap$3.31 billion
Myriad Genetics (NASDAQ:MYGN) Frequently Asked Questions
What is Myriad Genetics' stock symbol?
Myriad Genetics trades on the NASDAQ under the ticker symbol "MYGN."
How were Myriad Genetics' earnings last quarter?
Myriad Genetics, Inc. (NASDAQ:MYGN) posted its quarterly earnings data on Tuesday, August, 21st. The company reported $0.38 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.33 by $0.05. The business earned $200.90 million during the quarter, compared to the consensus estimate of $195.93 million. Myriad Genetics had a net margin of 17.69% and a return on equity of 9.78%. Myriad Genetics's quarterly revenue was up .7% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.30 EPS. View Myriad Genetics' Earnings History.
When is Myriad Genetics' next earnings date?
What guidance has Myriad Genetics issued on next quarter's earnings?
Myriad Genetics updated its FY19 earnings guidance on Tuesday, August, 21st. The company provided earnings per share (EPS) guidance of $1.70-1.75 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.43. The company issued revenue guidance of $880-890 million, compared to the consensus revenue estimate of $927.59 million.Myriad Genetics also updated its Q1 guidance to $0.28-0.30 EPS.
What price target have analysts set for MYGN?
9 analysts have issued 1-year target prices for Myriad Genetics' stock. Their forecasts range from $25.00 to $54.00. On average, they anticipate Myriad Genetics' stock price to reach $39.6667 in the next year. This suggests that the stock has a possible downside of 10.4%. View Analyst Price Targets for Myriad Genetics.
What is the consensus analysts' recommendation for Myriad Genetics?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Myriad Genetics in the last year. There are currently 3 sell ratings, 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Myriad Genetics.
What are Wall Street analysts saying about Myriad Genetics stock?
Here are some recent quotes from research analysts about Myriad Genetics stock:
- 1. According to Zacks Investment Research, "Myriad Genetics performed better than expected in fourth-quarter fiscal 2018. The company observed strong growth in GeneSight, Vectra DA, EndoPredict and Prolaris testing revenues. Further, management believes that Hereditary cancer pricing has remained stable on a sequential basis for three consecutive quarters. We are upbeat about Myriad Genetics’ expectation to witness a stable pricing trend throughout fiscal 2019. Moreover, the company seems to be positioned to deliver strong fiscal 2019 results on solid performance by new products, the recent Counsyl buyout, success of the Elevate 2020 program along with higher reimbursements for tests,. Accordingly, over the past three months, Myriad Genetics has outperformed its industry. However, the decline in Hereditary cancer testing revenues due to pricing issues raises concern. Currency fluctuations and stiff competition are other major headwinds." (8/27/2018)
- 2. Stephens analysts commented, "We initiate coverage of Nightstar Therapeutics (NITE) with a Buy rating (PT$40), on the market opportunity likely addressed by NSR- REP1 in choroideremia (CHM). Choroideremia is a rare, inherited degenerative disease of the retina that typically has onsets in childhood or early adolescence. Patients then progress to reach legal or complete blindness in their 40s or 50s. There are currently no FDA-approved disease-modifying therapies for CHM. Nightstar’s lead asset, AAV-based gene therapy, NSR-REP1, is due to enter the 140-patient pivotal phase III STAR trial in 1H18 for the treatment of CHM. With the Lancet-published phase I/II data for NSR-REP1 in CHM, and subsequent updates from the multi-center program, Nightstar has been able to show that all NSR-REP1- treated patients who received the therapeutic dose were able to maintain vision to 5 years after treatment." (1/3/2018)
Who are some of Myriad Genetics' key competitors?
Some companies that are related to Myriad Genetics include IPSEN S A/S (IPSEY), Immunomedics (IMMU), Neogen (NEOG), Quidel (QDEL), Intellia Therapeutics (NTLA), Meridian Bioscience (VIVO), Lantheus (LNTH), Oxford Immunotec Global (OXFD), Quotient (QTNT), Nymox Pharmaceutical (NYMX), Trinity Biotech (TRIB), Celldex Therapeutics (CLDX), ImmuCell (ICCC), Vermillion (VRML) and Riot Blockchain (RIOT).
Who are Myriad Genetics' key executives?
Myriad Genetics' management team includes the folowing people:
- Mr. Mark Christopher Capone, CEO, Pres & Director (Age 56)
- Mr. R. Bryan Riggsbee, Exec. VP, CFO & Treasurer (Age 47)
- Dr. Jerry S. Lanchbury, Chief Scientific Officer (Age 59)
- Mr. Richard M. Marsh, Exec. VP, Gen. Counsel & Sec. (Age 60)
- Mr. Alexander Ford, Pres of Myriad Women's Health (Age 51)
Who are Myriad Genetics' major shareholders?
Myriad Genetics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Bank of Montreal Can (0.13%), GHP Investment Advisors Inc. (0.08%), BB&T Corp (0.08%), Taylor Frigon Capital Management LLC (0.06%), Seven Eight Capital LP (0.04%) and Strs Ohio (0.04%). Company insiders that own Myriad Genetics stock include Alexander Ford, Dennis Langer, Gary A King, Heinrich Dreismann, Jerry S Lanchbury, John T Henderson, Mark Christopher Capone, Richard M Marsh and Walter Phd Gilbert. View Institutional Ownership Trends for Myriad Genetics.
Which institutional investors are selling Myriad Genetics stock?
MYGN stock was sold by a variety of institutional investors in the last quarter, including Fox Run Management L.L.C., BB&T Corp, Taylor Frigon Capital Management LLC and Strs Ohio. Company insiders that have sold Myriad Genetics company stock in the last year include Alexander Ford, Dennis Langer, Gary A King, Heinrich Dreismann, Jerry S Lanchbury, John T Henderson, Mark Christopher Capone, Richard M Marsh and Walter Phd Gilbert. View Insider Buying and Selling for Myriad Genetics.
Which institutional investors are buying Myriad Genetics stock?
MYGN stock was acquired by a variety of institutional investors in the last quarter, including Seven Eight Capital LP, Bank of Montreal Can, GHP Investment Advisors Inc., CHICAGO TRUST Co NA and Bowling Portfolio Management LLC. View Insider Buying and Selling for Myriad Genetics.
How do I buy shares of Myriad Genetics?
Shares of MYGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Myriad Genetics' stock price today?
One share of MYGN stock can currently be purchased for approximately $44.26.
How big of a company is Myriad Genetics?
Myriad Genetics has a market capitalization of $3.31 billion and generates $772.60 million in revenue each year. The company earns $131.10 million in net income (profit) each year or $1.20 on an earnings per share basis. Myriad Genetics employs 2,400 workers across the globe.
What is Myriad Genetics' official website?
How can I contact Myriad Genetics?
Myriad Genetics' mailing address is 320 WAKARA WAY, SALT LAKE CITY UT, 84108. The company can be reached via phone at 801-584-3600 or via email at [email protected]
MarketBeat Community Rating for Myriad Genetics (NASDAQ MYGN)
MarketBeat's community ratings are surveys of what our community members think about Myriad Genetics and other stocks. Vote "Outperform" if you believe MYGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MYGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
